$PGEN

Shah Rutul R sold $251K of PGEN

Shah Rutul R (Chief Operating Officer) sold 42,924 shares of PRECIGEN, INC. (PGEN) at $5.85 ($0.25M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shah Rutul R
Published Jul 1, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGEN
Neutral
high confidence
Mentioned
$PGEN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The only new fact is the disclosed sale size, price, and post-transaction holdings; it does not include guidance, trial results, or regulatory updates.

02

Market read

Traders may monitor insider activity for sentiment, but 10b5-1 sales typically carry less informational weight than unscheduled sales.

03

What to watch

The filing doesn’t disclose reasons for the sale beyond the plan; without accompanying buy/sell patterns or new company events, trading impact should be limited.

Relevance 3/10Novelty 3/10Timing: Filed after-hours on 2026-07-01; reflects sale executed 2026-06-29.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Precigen, Inc.

Company-level read

Ticker impact

$PGENNeutralHigh confidence
Context

SEC Form 4 shows COO Shah Rutul R sold 42,924 shares of Precigen at $5.85 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no new operating, regulatory, or financial datapoints.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical rather than a bearish view on prospects.

Key entities

  • PRECIGEN, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Shah Rutul R

    Chief Operating Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

$PGENMed

Precigen (PGEN) Q2 2026 Earnings Call Transcript

Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.

$PGENMed

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro